# Tuning, Rather than Blocking, Immunity in IBD

Page: https://stenobird.com/podcast/the-bio-report-1092382/tuning-rather-than-blocking-immunity-in-ibd
Text version: https://stenobird.com/podcast/the-bio-report-1092382/tuning-rather-than-blocking-immunity-in-ibd.md
Podcast: [The Bio Report](https://stenobird.com/podcast/the-bio-report-1092382)
Published: 2026-04-15T07:00:00+00:00
Episode link: https://thebioreport.podbean.com/e/tuning-rather-than-blocking-immunity-in-ibd/
Audio file: https://mcdn.podbean.com/mf/web/bwwayzd9jc462bey/BR-Marc_de_Garidel_-4-15-26b79ww.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/the-bio-report-1092382/episodes/tuning-rather-than-blocking-immunity-in-ibd
Duration seconds: 2147

## Resource

The treatment of inflammatory bowel disease currently relies on immunosuppressive therapies that often lose effectiveness, carry infection risks, and drive high treatment cycling. Abivax is betting that fine-tuning, rather than suppressing, the immune system can reshape the treatment paradigm in IBD. Marc de Garidel, CEO of Abivax, discusses how a once-failed HIV candidate evolved into a late‑stage oral IBD therapy that may deliver durable remission, how it acts upstream of key inflammatory pathways, and its potential in a crowded but still underserved IBD market.

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/the-bio-report-1092382/episodes/tuning-rather-than-blocking-immunity-in-ibd/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/the-bio-report-1092382/tuning-rather-than-blocking-immunity-in-ibd.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.